neurocognitive decline in patients with brain metastases

Conditions: Brain Metastases

Summary: the phase i component of the study is to identify maximal tolerated dose (mtd). the phase ii is to evaluate neurocognitive decline.

on review of our experience with treatment for brain metastases since 2009, we have treated over 100 patients with 6 or more metastases in a single radiosurgery session. in the past year and a half (2015-16) there have been approximately 50 patients treated with six or more metastases, indicating that there has been a shift in management of intracranial metastatic disease with increasing preference for radiosurgery despite the presences of greater metastatic burden. the phase i component will accrue 7-15 patients at each dose cohort until the mtd is determined. once the mtd is reached, the phase ii component will commence with a total of 50 patients total enrolled at the mtd, with a study time of 3 years. the primary endpoint of the phase i component is toxicity. the primary endpoint of the phase ii component is the change in neurocognitive function, defined by a decline in the hopkins verbal learning test- revised delayed recall. data from the wbrt-alone arm of the pci-p-120-9801 phase iii trial evaluating wbrt plus motexafin gadolinium demonstrated a 30% mean relative decline in the hvlt-r delayed recall score from baseline to 4 months, with a standard deviation of 41% 9,10. more recently, in patients treated with srs alone for 1-3 metastases versus srs plus whole brain radiotherapy, the 4-month rates of hvlt-r delayed recall deterioration were 6% and 22% for the srs alone arm and srs + whole brain radiotherapy arm, respectively. given the greater intracranial burden of disease, we estimate the mean relative decline in hvlt-r delayed recall to be intermediate between srs alone for 1-3 metastases and whole brain radiotherapy. we predict that after srs for multiple metastases the mean relative decline in delayed recall as 15%, an improvement over the historical control of whole brain radiotherapy alone which had a mean relative decline in hvlt-r delayed recall of 30%.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. ecog performance score of 2 or better/karnofsky performance score of 50-60 or better. 3. biopsy-proven non-hematopoietic malignancy, except for germ cell cancer. small cell lung carcinoma is eligible for this study. 4. six or more metastases on diagnostic or treatment planning imaging, which include either ct brain (with contrast) or mr brain (with or without contrast) imaging. 5. largest tumor \<= 4 cm. 6. no prior srs to the lesions which will be treated on protocol. 7. women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. a female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * has not undergone a hysterectomy or bilateral oophorectomy; or * has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). 8. ability to understand and the willingness to sign a written informed consent. exclusion criteria: 1. prior whole brain radiotherapy 2. patients with leptomeningeal metastasis. (note: for the purposes of exclusion, lmd is a clinical diagnosis, defined as positive csf cytology and/or equivocal radiologic or clinical evidence of leptomeningeal involvement. patients with leptomeningeal symptoms in the setting of leptomeningeal enhancement by imaging (mri) would be considered to have lmd even in the absence of positive csf cytology, unless a parenchymal lesion can adequately explain the neurologic symptoms and/or signs. in contrast, an asymptomatic or minimally symptomatic patient with mild or nonspecific leptomeningeal enhancement (mri) would not be considered to have lmd. in that patient, csf sampling is not required to formally exclude lmd, but can be performed at the investigator's discretion based on level of clinical suspicion.) 3. patients with life expectancy \< 4 months. 4. psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements. 5. subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.